These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

278 related articles for article (PubMed ID: 37190153)

  • 1. Cardiotoxicity, Cardioprotection, and Prognosis in Survivors of Anticancer Treatment Undergoing Cardiac Surgery: Unmet Needs.
    Palmieri V; Vietri MT; Montalto A; Montisci A; Donatelli F; Coscioni E; Napoli C
    Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190153
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Redox Imbalances in Ageing and Metabolic Alterations: Implications in Cancer and Cardiac Diseases. An Overview from the Working Group of Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology (SIC).
    Mercurio V; Cuomo A; Cadeddu Dessalvi C; Deidda M; Di Lisi D; Novo G; Manganaro R; Zito C; Santoro C; Ameri P; Spallarossa P; Arboscello E; Tocchetti CG; Penna C
    Antioxidants (Basel); 2020 Jul; 9(7):. PubMed ID: 32708201
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cardio-oncology, the myth of Sisyphus, and cardiovascular disease in breast cancer survivors.
    Mavrogeni SI; Sfendouraki E; Markousis-Mavrogenis G; Rigopoulos A; Noutsias M; Kolovou G; Angeli C; Tousoulis D
    Heart Fail Rev; 2019 Nov; 24(6):977-987. PubMed ID: 31134427
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of valvular heart disease in patients with cancer: Multidisciplinary team, cancer-therapy related cardiotoxicity, diagnosis, transcatheter intervention, and cardiac surgery. Expert opinion of the Association on Valvular Heart Disease, Association of Cardiovascular Interventions, and Working Group on Cardiac Surgery of the Polish Cardiac Society.
    Płońska-Gościniak E; Piotrowski G; Wojakowski W; Gościniak P; Olszowska M; Lesiak M; Klotzka A; Grygier M; Deja M; Kasprzak JD; Kukulski T; Kosmala W; Suwalski P; Kolowca M; Widenka K; Hryniewiecki T
    Kardiol Pol; 2023; 81(1):82-101. PubMed ID: 36641646
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of cardiotoxicity related to non-small cell lung cancer (NSCLC) treatments: A systematic review.
    Chan SHY; Khatib Y; Webley S; Layton D; Salek S
    Front Pharmacol; 2023; 14():1137983. PubMed ID: 37383708
    [No Abstract]   [Full Text] [Related]  

  • 6. Cardiotoxicity of Anticancer Drugs: Molecular Mechanisms and Strategies for Cardioprotection.
    Morelli MB; Bongiovanni C; Da Pra S; Miano C; Sacchi F; Lauriola M; D'Uva G
    Front Cardiovasc Med; 2022; 9():847012. PubMed ID: 35497981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer.
    Sieswerda E; van Dalen EC; Postma A; Cheuk DK; Caron HN; Kremer LC
    Cochrane Database Syst Rev; 2011 Sep; (9):CD008011. PubMed ID: 21901716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cardiotoxicity of anticancer treatments: Epidemiology, detection, and management.
    Curigliano G; Cardinale D; Dent S; Criscitiello C; Aseyev O; Lenihan D; Cipolla CM
    CA Cancer J Clin; 2016 Jul; 66(4):309-25. PubMed ID: 26919165
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart.
    Tocchetti CG; Ameri P; de Boer RA; D'Alessandra Y; Russo M; Sorriento D; Ciccarelli M; Kiss B; Bertrand L; Dawson D; Falcao-Pires I; Giacca M; Hamdani N; Linke WA; Mayr M; van der Velden J; Zacchigna S; Ghigo A; Hirsch E; Lyon AR; Görbe A; Ferdinandy P; Madonna R; Heymans S; Thum T
    Cardiovasc Res; 2020 Sep; 116(11):1820-1834. PubMed ID: 32683451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiac complications in childhood cancer survivors treated with anthracyclines.
    Franco VI; Lipshultz SE
    Cardiol Young; 2015 Aug; 25 Suppl 2():107-16. PubMed ID: 26377717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of QT prolongation induced by anti-cancer drugs: Target therapy and old agents. Different algorithms for different drugs.
    Coppola C; Rienzo A; Piscopo G; Barbieri A; Arra C; Maurea N
    Cancer Treat Rev; 2018 Feb; 63():135-143. PubMed ID: 29304463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategies to Prevent Cardiotoxicity.
    Graffagnino J; Kondapalli L; Arora G; Hawi R; Lenneman CG
    Curr Treat Options Oncol; 2020 Apr; 21(4):32. PubMed ID: 32270293
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging Cardiac Imaging Modalities for the Early Detection of Cardiotoxicity Due to Anticancer Therapies.
    López-Fernández T; Thavendiranathan P
    Rev Esp Cardiol (Engl Ed); 2017 Jun; 70(6):487-495. PubMed ID: 28189542
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heart Disease Mortality in the Life Span Study, 1950-2008.
    Takahashi I; Shimizu Y; Grant EJ; Cologne J; Ozasa K; Kodama K
    Radiat Res; 2017 Mar; 187(3):319-332. PubMed ID: 28170314
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Heartbreaker: Detection and prevention of cardiotoxicity in hematological malignancies.
    Vakilpour A; Lefebvre B; Lai C; Scherrer-Crosbie M
    Blood Rev; 2024 Mar; 64():101166. PubMed ID: 38182490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Late Cardiotoxicity: Issues for Childhood Cancer Survivors.
    Akam-Venkata J; Franco VI; Lipshultz SE
    Curr Treat Options Cardiovasc Med; 2016 Jul; 18(7):47. PubMed ID: 27230282
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Educational paper: decreasing the burden of cardiovascular disease in childhood cancer survivors: an update for the pediatrician.
    Dillenburg RF; Nathan P; Mertens L
    Eur J Pediatr; 2013 Sep; 172(9):1149-60. PubMed ID: 23361962
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Arterial Hypertension and Hypertension-Mediated Organ Damage in Cardiotoxicity of Anticancer Therapies.
    Tini G; Tocci G; Battistoni A; Sarocchi M; Pietrantoni C; Russo D; Musumeci B; Savoia C; Volpe M; Spallarossa P
    Curr Heart Fail Rep; 2023 Feb; 20(1):56-62. PubMed ID: 36696001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Models of Heart Failure Based on the Cardiotoxicity of Anticancer Drugs.
    Mercurio V; Pirozzi F; Lazzarini E; Marone G; Rizzo P; Agnetti G; Tocchetti CG; Ghigo A; Ameri P
    J Card Fail; 2016 Jun; 22(6):449-58. PubMed ID: 27103426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiotoxicity model-based patient selection for Hodgkin lymphoma proton therapy.
    Loap P; Orlandi E; De Marzi L; Vitolo V; Barcellini A; Iannalfi A; Dendale R; Kirova Y; Mirandola A
    Acta Oncol; 2022 Aug; 61(8):979-986. PubMed ID: 35668710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.